CTOs on the Move

Genentech

www.genetech.com

 
Genentech, Inc., is a biotechnology corporation which became a subsidiary of Roche in 2009.
  • Number of Employees: 5K-10K
  • Annual Revenue: $0-1 Million
  • www.genetech.com
  • 1, DNA Way
    South San Francisco, CA USA 94080
  • Phone: 650.225.1000

Executives

Name Title Contact Details

Similar Companies

KBI BioPharma

KBI BioPharma is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Regen BioPharma

The focus of Regen BioPharma, Inc. is to developing translational medicine platforms for the rapid commercialization of stem cell therapies and to advance intellectual property licensed from entities, institutions and universities that show promise towards fulfilling the purpose of increased quality of life. Regen BioPharma has reviewed more than 20,000 US issued patents covering stem cell related subject matter, created a shortlist of 30 promising technologies for rapid commercialization, and currently is in negotiations to license several of these. The Regen BioPharma business model is to take multiple stem cell therapeutics to and through the human "safety and signal of efficacy" stage (Phase I/II clinical trials), followed by exit. Having assembled a core infrastructure specialized in obtaining regulatory approval and executing clinical trials in cell therapy, we aim to act as a "superincubator" that within 1-2 years grows technologies from laboratory to an asset ready for spin-off or sale.

Metametrix

Metametrix is a Duluth, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

biozeen

biozeen is a Allentown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Five Prime Therapeutics

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company`s product candidates include FP-1039/GSK3052230, a protein therapeutic is in PhaseIb clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, an antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumors. It has collaboration and license agreements with GlaxoSmithKline LLC, Glaxo Group Limited, GSK-HGS, Pfizer Inc., and UCB Pharma S.A. The company was founded in 2001 and is headquartered in South San Francisco, California.